Destiny Pharma PLC (AIM:DEST) said it is ‘close’ to delivering a partnering deal for NTCD-M3, which has been developed to prevent C.difficile infections (CDI).
It would be the next stage in the journey for the asset, which was acquired in November 2020 and is now phase III-ready thanks to the company’s regulatory, clinical and manufacturing efforts.
Destiny provided an update in an overview briefing of its progress to date, which also charted the steps forward it has made with its second major asset, XF-73 Nasal, designed to prevent post-surgical Staphylococcus aureus infections.
Feedback from the US regulator, the Food & Drug Administration, means it is now well prepared for a phase III evaluation of the asset.
Both drugs have the potential to generate annual sales in excess of US$1bn a year, which would place them in the blockbuster category.
“I am extremely positive on the future of Destiny Pharma and I believe that our products can have a major impact in reducing infections worldwide and reduce healthcare costs,” said chairman Nick Rodgers.
“Our commitment to infection prevention is more relevant than ever and we have a very large opportunity to create significant value for our stakeholders including patients, healthcare systems and payers."